Publications by authors named "Donald Kellerman"

Claim this Profile
L
Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine.
Stephanie J Nahas, Nada Hindiyeh, Deborah I Friedman, Nada Elbuluk, Donald J Kellerman

J Headache Pain· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta™) for the acute treatment of migraine.
Alan M Rapoport, Mahmoud Ameri, Hayley Lewis, Donald J Kellerman

Pain Manag· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.
Nada A Hindiyeh, Donald J Kellerman, Peter C Schmidt

Headache· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
Stewart J Tepper, David W Dodick, Peter C Schmidt, Donald J Kellerman

Headache· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.
David W Dodick, Stewart J Tepper, Deborah I Friedman, Amy A Gelfand, Donald J Kellerman

Headache· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
Egilius Lh Spierings, Jan Lewis Brandes, David B Kudrow, James Weintraub, Peter C Schmidt, Donald J Kellerman

Cephalalgia· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid systemic delivery of zolmitriptan using an adhesive dermally applied microarray.
Donald J Kellerman, Mahmoud Ameri, Stewart J Tepper

Pain Manag· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
Robert J Noveck, Pamela S Douglas, Shein-Chung Chow, Barry Mangum, Shashidhar Kori, Donald J Kellerman

Drug Des Devel Ther· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
Donald J Kellerman, Amy Forst, Daniel L Combs, Scott Borland, Shashidhar Kori

J Aerosol Med Pulm Drug Deliv· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Shashidhar Kori, Donald J Kellerman, Polina Voloshko, Gregory Haugen

Clin Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.
Donald Kellerman, Andrea Rossi Mospan, Jean Engels, Amy Schaberg, Joann Gorden

Pulm Pharmacol Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
Fred L Johnson, José L Boyer, Philip T Leese, Christopher Crean, Ramesh Krishnamoorthy, Donald J Kellerman

Platelets· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diquafosol tetrasodium: a novel dry eye therapy.
Kelly K Nichols, Ben Yerxa, Donald J Kellerman

Expert Opin Investig Drugs· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.
Benjamin R Yerxa, Mohan Mundasad, Robin N Sylvester, JoAnn C Garden, Mark Cooper, Donald J Kellerman

Adv Exp Med Biol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.
Donald J Kellerman

Chest· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluticasone Propionate Reduces Oral Prednisone Use While it Improves Asthma Control.
Michael Noonan, Paul Chervinsky, William W. Busse, Steven C. Weisberg, Jacob Pinnas, Donald Kellerman

Am J Ther· July 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis